Divi's Laboratories Limited is a Pharmaceuticals company listed on the National Stock Exchange (NSE) with a market capitalisation of ₹3.04 lakh crore. The company reports ROE of 20.1%, a net profit margin of 27.6%. Revenue grew +35.4% year-over-year. Promoter holding stands at 52%, with FII participation at 29.9%.
Price is rising consistently (EMA alignment — short and medium-term averages both pointing up). Buying pressure is building (RSI/MACD momentum confirmed). Trading near its strongest price of the year (within 5% of 52-week high). Company earns strong returns on shareholder money (ROE 20.1% — above 15% benchmark). A trend-following indicator is on the bullish side (SuperTrend signal: buy). The uptrend is visible even on the weekly chart (longer-term trend confirmed). Each rally is higher than the last, and each dip is shallower (higher highs and higher lows — healthy uptrend structure). Short-term oscillator is overheated — entering now means chasing (StochRSI above 80, late entry risk). Both short and medium-term trend lines are pointing upward — the trend has momentum (rising EMA20 + EMA50). Foreign institutions have been net buyers for 3 consecutive days — sustained institutional demand (✅ FII buying streak).
Divi's Laboratories Limited scores 72/100 (High Conviction Research Signal). The strongest signals are Trend (17/100) and Momentum (11/100). The weakest dimension is Valuation (0/100), which warrants monitoring. This reflects JaySense quantitative research scoring only — not investment advice. Consult a SEBI Registered Investment Adviser before making any investment decision.
| Stock | Score | Signal |
|---|---|---|
|
SUNPHARMA
Sun Pharmaceutical Industries Limited
|
84 | High Conviction |
|
AUROPHARMA
Aurobindo Pharma Limited
|
75 | High Conviction |
|
APOLLOHOSP
Apollo Hospitals Enterprise Limited
|
73 | High Conviction |
|
CIPLA
Cipla Limited
|
69 | Positive Setup |
|
GLENMARK
Glenmark Pharmaceuticals Limited
|
60 | Positive Setup |